Home/Pipeline/Remibrutinib (LOU064)

Remibrutinib (LOU064)

Chronic Spontaneous Urticaria (CSU)

Phase IIIActiveN/A

Key Facts

Indication

Chronic Spontaneous Urticaria (CSU)

Phase

Phase III

Status

Active

Company

Novartis

About Novartis

Novartis is a global pharmaceutical leader with a mission to reimagine medicine to improve and extend lives. With a market cap of $290.10B, it operates across 118 countries, reaching over 300 million patients annually. Its strategy focuses on delivering high-value medicines for society's greatest disease burdens through technology leadership in R&D and novel access approaches, powered by a diversified portfolio across oncology, cardiovascular, immunology, neuroscience, and rare diseases.

View full company profile

Therapeutic Areas

Cardiovascular, Renal and Metabolic Immunology Neuroscience Oncology

Other Chronic Spontaneous Urticaria (CSU) Drugs

Drug	Company	Phase	Status
Barzolvolimab	Celldex Therapeutics	Phase 3	Active
THB001	Third Harmonic Bio	Phase 1b	Active, Recruiting